Setting Expectations and Starting UPTRAVI

Starting Your PAH Patients on UPTRAVI—Setting Treatment Goals and Expectations

When you decide to start your patient on treatment with UPTRAVI, it’s important to set goals and expectations with them.

  • Ask patients what’s most important to them in their treatment with UPTRAVI. Let them know what to expect and who to contact to help
    them and their loved ones be prepared for treatment

UPTRAVI Dose Adjustment Phase—Helps Meet Individual Patient Needs1

UPTRAVI dosing is unique to each patient based on how their body responds and adjusts to treatment. The dose adjustment phase is how you find your patient’s personal dose.

Tablet not shown at actual size.

*Once daily for patients with moderate hepatic impairment and co-administration with moderate CYP2C8 Inhibitors.

Recommended starting dose is 200 mcg twice daily. Tolerability may be improved when taken with food. Increase by 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1600 mcg twice daily. If dose is not tolerated, reduce to the previous tolerated dose.

  • If a dose of UPTRAVI is missed, patients should take the missed dose as soon as possible unless the next dose is within the next 6 hours
  • If treatment is missed for 3 days or more, restart UPTRAVI at a lower dose and then retitrate
The goal is to reach the dose that’s right for each patient, not necessarily to reach 1600 mcg

After the dose adjustment phase1

Once each patient reaches their personal dose (maintenance), a single-tablet equivalent is prescribed BID. There are 8 different single-tablet strengths of UPTRAVI, each a unique color.

UPTRAVI OFFERS A RANGE OF DOSE STRENGTHS TO ACCOMMODATE EACH PATIENT’s personal dose

200 mcg Light yellow
400 mcg Red
600 mcg Light violet
800 mcg Green
1000 mcg Orange
1200 mcg Dark violet
1400 mcg Dark yellow
1600 mcg Brown
Size shown in relation to a dime for proportional comparison. Tablet not shown at actual size. Actual tablet size is 7 mm.

TREATMENT EFFECT OF UPTRAVI WAS CONSISTENT, REGARDLESS OF THE PERSONAL DOSE ACHIEVED1,2

Time to first disease progression event in GRIPHON by dose group

Efficacy by dose group:

  • 40%
    RISK REDUCTION
    (low dose:
    200 mcg to 400 mcg)

    HR 0.60 (95% CI: 0.41, 0.88)
  • 47%
    RISK REDUCTION
    (medium dose:
    600 mcg to 1000 mcg)

    HR 0.53 (95% CI: 0.38, 0.72)
  • 36%
    RISK REDUCTION
    (high dose:
    1200 mcg to 1600 mcg)

    HR 0.64 (95% CI: 0.49, 0.82)

UPTRAVI doses were achieved across the 3 prespecified groups in the GRIPHON trial

  • 200 mcg to 400 mcg BID (low dose): 23% of patients (n=133)
  • 600 mcg to 1000 mcg BID (medium dose): 31% of patients (n=179)
  • 1200 mcg to 1600 mcg BID (high dose): 43% of patients (n=246)